Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31662487 | 1.00 | CA12 (0.39) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL766879 | 0.92 | CA12 (0.41) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL3110871 | 0.90 | CYP2D6 (0.41) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL23273024 | 0.87 | CYP3A4 (0.42) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL3387501 | 0.86 | ALDH1A1 (0.44) | MEN1KMT2ACYP2D6CYP1A2CYP3A4 | |
| SCHEMBL13097208 | 0.86 | CA12 (0.41) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL13025640 | 0.85 | ESR1 (0.42) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL11848457 | 0.84 | ESR1 (0.43) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL7372412 | 0.83 | HTR6 (0.46) | CA12CA1CA9CYP2D6CYP1A2 | |
| SCHEMBL25907366 | 0.83 | ALDH1A1 (0.41) | CA12CA1CA9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392298-B1 | FUSED HETEROCYCLIC COMPOUNDS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070135425-A1 | Fused heterocyclic compounds | AMGEN INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7125885-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050148617-A1 | Fused heterocyclic compounds | TULARIK INC. | 2005-07-07 | — | — | US | disclosed |
| EP-1392298-A4 | FUSED HETEROCYCLIC COMPOUNDS | TULARIK INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6858619-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6809104-B2 | COMPRISES 6H-PYRIDO(4,3-B)CARBAZOLE-CONTAINING COMPOUNDS FOR TREATMENT OF OBESITY, EATING/ANXIETY/MOOD DISORDERS AND OTHER DISEASES MEDIATED BY G-PROTEIN-COUPLED-RECEPTORS AND MELANIN-CONCENTRATING HORMONE RECEPTORS | TULARIK INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1392298-A2 | FUSED HETEROCYCLIC COMPOUNDS | Tularik Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030176694-A1 | Fused heterocyclic compounds | AMGEN INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030023085-A1 | Fused heterocyclic compounds | TULARIK INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002089729-A2 | FUSED HETEROCYCLIC COMPOUNDS | TULARIK INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023085-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | CA12 3642/4885CA1 3170/4885CA9 3692/4885 |
| US-20050148617-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | CA12 3642/4885CA1 3170/4885CA9 3692/4885 |
| US-20030176694-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | CA12 3642/4885CA1 3170/4885CA9 3692/4885 |
| US-20070135425-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | CA12 3642/4885CA1 3170/4885CA9 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.